欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是

中国临床药理学与治疗学 ›› 2022, Vol. 27 ›› Issue (4): 405-408.doi: 10.12092/j.issn.1009-2501.2022.04.008

• 心血管疾病药物治疗最新研究进展 • 上一篇    下一篇

冠心病药物治疗进展

常书福   

  1. 复旦大学附属中山医院心内科,上海市心血管病研究所,上海市放射与治疗(介入治疗)临床医学研究中心,国家放射与治疗临床医学研究中心,上海 200032
  • 出版日期:2022-04-26 发布日期:2022-05-17
  • 作者简介:常书福,男,博士,主治医师,研究方向:冠心病药物及介入治疗。 E-mail: chang.shufu@zs-hospital.sh.cn
  • 基金资助:
    上海市卫生健康委员会科研课题面上项目(201940152)

Progress of medical treatment of coronary heart disease

CHANG Shufu    

  1. Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, Shanghai Clinical Research Center for Interventional Medicine, National Clinical Research Center for Interventional Medicine, Shanghai 200032, China
  • Online:2022-04-26 Published:2022-05-17

摘要: 冠心病治疗方法日新月异,不断有新型药物进入临床。抗血小板药物是冠心病治疗的基础,但目前尚无新型药物能撼动阿司匹林和P2Y12受体抑制剂的地位。炎症与冠心病的发生发展息息相关,抗炎治疗初露曙光,仍需进一步深入探索。本文拟就冠心病药物治疗的进展进行总结,为临床实践提供新的视野。

关键词: 冠心病, 抗血小板, 炎症

Abstract: Coronary heart disease (CHD) treatment methods are changing rapidly, and new drugs are constantly entering the clinic. Antiplatelet drugs are the basis for the treatment of CHD, but there are currently no new drugs that can challenge the status of aspirin and P2Y12 receptor inhibitors. Inflammation is the mechanism of the occurrence and development of CHD, and anti-inflammatory treatment is just beginning, and further exploration is still needed. This paper aims to summarize the progress of drug treatment for CHD and provide a new perspective for clinical practice.

Key words: coronary heart disease, antiplatelet, inflammation

中图分类号: